Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Insights on the downsides of late-night screen time and health benefits of digital detox April 27, 2024 Extreme heat alert: Understanding the impact of heatwaves on public health July 19, 2024 Family member’s cancer diagnosis may increase risks of psychological and cardiovascular illnesses September 15, 2024
Insights on the downsides of late-night screen time and health benefits of digital detox April 27, 2024
Family member’s cancer diagnosis may increase risks of psychological and cardiovascular illnesses September 15, 2024